American Biogenetic Sciences Inc. - Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Statements of Cash Flows
Net loss	(28,896)	(52,840)
Expenses paid by issuance of common stock	0	0
Fair value of services provided by related parties	0	42,000
Increase (decrease) in accounts payable and accrued expenses	14,021	10,840
Cash flows used by operating activities	$ (14,875)	$ 0
Cash used in investing activities	0	0
Advances from related parties	14,875	0
Cash generated by financing activities	14,875	0
Change in cash	$ 0	$ 0
Cash - beginning of period	0	0
Cash - end of period	0	0